Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

Par Generic Fluoxetine Expected To Launch In Three Strengths On Aug. 2

  • News

Executive Summary

Par plans to launch 10 mg, 20 mg and 40 mg strengths of fluoxetine Aug. 2 following the expiry of Lilly's pediatric exclusivity for Prozac.

You may also be interested in...



Geneva Claims Fluoxetine 10 Mg Cap Exclusivity; Barr Restates Cipro Income

Geneva is reclaiming sole rights to the generic exclusivity for the 10 mg capsule form of fluoxetine.

Geneva Claims Fluoxetine 10 Mg Cap Exclusivity; Barr Restates Cipro Income

Geneva is reclaiming sole rights to the generic exclusivity for the 10 mg capsule form of fluoxetine.

Dr. Reddy's Looks To Acquire U.S. Generics Company Following $115 Mil. IPO

Dr. Reddy's Laboratories plans to expand its presence in the U.S. generics market through acquisitions following its April 11 initial public offering.

Table

View full table

Related Content

Pink Sheet
Tags:
Latest Headlines

Generic Or Innovator? Sandoz Sues CMS Over Potential Change In Rebate Classification

US FDA Gene Therapy Accelerated Approval Guidance Will Describe ‘Buckets’ Of Use Scenarios

FTC Early Findings In PBM Investigation Coming By Mid-Summer, Chair Kahn Says

New EU Filings

See All
UsernamePublicRestriction

Register

PS037765

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By